Vancomycin-Resistant Enterococci

VRE Basics - Entero Invaders

• Enterococci: Gram-positive cocci, normal flora of the gastrointestinal tract (GIT) & female genitourinary tract (GUT). They are opportunistic pathogens.
  • Common species: Enterococcus faecalis (more prevalent), Enterococcus faecium.
• Vancomycin-Resistant Enterococci (VRE): Strains of enterococci that are resistant to the antibiotic vancomycin.
  • A significant nosocomial (hospital-acquired) pathogen, especially problematic in immunocompromised patients and those in intensive care units (ICUs).
• Key Risk Factors for VRE Acquisition/Infection:
  • Prolonged hospitalization.
  • Previous or current use of vancomycin or broad-spectrum antibiotics.
  • ICU stay.
  • Presence of indwelling medical devices (e.g., urinary catheters, central venous catheters).
  • Immunosuppression (e.g., organ transplant recipients, patients on chemotherapy).
• Epidemiology in India: VRE is a notable and increasingly reported cause of nosocomial infections in Indian healthcare settings.

⭐ Enterococcus faecium is more commonly associated with vancomycin resistance and typically results in infections that are harder to treat compared to Enterococcus faecalis.

Resistance Mechanism - Vancomycin's Vanquishers

Acquired resistance via modification of vancomycin's target site.

• Core Mechanism: Alteration of peptidoglycan (PG) precursor.
  • Normal PG terminus: D-Ala-D-Ala.
  • VRE: Synthesis of D-Ala-D-Lactate (D-Ala-D-Lac) or D-Ala-D-Serine (D-Ala-D-Ser).
  • Vancomycin binding affinity ↓ (e.g., D-Ala-D-Ala $\rightarrow$ D-Ala-D-Lac).
• Genetic Basis: Acquired van operons on mobile elements (plasmids, transposons e.g., Tn1546 for vanA).

⭐ The VanA phenotype confers high-level, inducible resistance to both vancomycin and teicoplanin and is typically plasmid-mediated via the Tn1546 transposon.

Key Van Phenotypes:

Clinical Picture & Diagnosis - VRE's Vexations

• Common VRE Infections:
  • Urinary Tract Infections (UTIs)
  • Bacteremia/Sepsis
  • Endocarditis
  • Surgical Site/Wound Infections
  • Intra-abdominal Infections
• Symptoms: Non-specific, vary with infection site.
• Laboratory Diagnosis:
  • Culture: From relevant sites (blood, urine, wound).
  • Identification: Enterococcus species.
  • Antimicrobial Susceptibility Testing (AST):
    • Methods: Disk diffusion, MIC (broth dilution, E-test).
    • Interpretation: Vancomycin MIC ≥32 µg/mL (CLSI/EUCAST criteria).
  • Screening: Rectal swabs for VRE colonization (outbreaks, high-risk patients).
  • Molecular: PCR for vanA, vanB genes (rapid detection).

⭐ VRE bacteremia is associated with significant mortality, particularly in critically ill or immunocompromised patients.

Treatment & Prevention - Vanquishing VRE

Treating VRE is challenging (MDR).

• Therapeutic Agents:

  Drug	Target VRE Species	Key Points/Dose
  Linezolid	E. faecalis, E. faecium	600mg IV/PO q12h; Good oral bioavailability
  Daptomycin	E. faecalis, E. faecium	6-12 mg/kg IV q24h; Not for pneumonia
  Tigecycline	E. faecalis, E. faecium	Bacteriostatic for VRE; Caution
  Quinupristin-Dalfopristin	E. faecium VRE only	Not for E. faecalis (intrinsic resistance)

  • Newer agents: Tedizolid, Oritavancin, Dalbavancin active.
  • Combination therapy for severe infections.
  • Crucial: Source control (e.g., catheter removal).

⭐ Linezolid: often first-line for VRE due to oral bioavailability & activity vs E. faecalis & E. faecium.

• Infection Prevention & Control (IPC):
  • 📌 CHASE VRE:
    • Contact precautions (gloves, gowns)
    • Hand hygiene
    • Antibiotic stewardship
    • Screening high-risk
    • Environmental cleaning
  • Patient isolation/cohorting.

High‑Yield Points - ⚡ Biggest Takeaways

• Enterococci (E. faecalis, E. faecium) are normal gut flora, causing opportunistic infections like UTIs.
• VRE primarily via VanA gene (high-level resistance), altering D-Ala-D-Ala to D-Ala-D-Lac in cell wall synthesis.
• Key risk factors: Prolonged hospitalization, prior vancomycin/broad-spectrum antibiotic use, immunocompromised state.
• Common VRE infections: Urinary Tract Infections (UTIs), bacteremia, endocarditis, and surgical site/wound infections.
• Treatment mainstays: Linezolid, Daptomycin; Tigecycline for complicated or resistant infections.
• Strict infection control measures (hand hygiene, contact precautions) are paramount for VRE prevention and control in healthcare settings.